Brokerages Stay Bullish on Laurus Labs as CDMO Momentum Strengthens

Laurus Labs has captured analyst attention following robust financial results for FY26, with the company's stock advancing 30%, according to reports. The pharmaceutical contract development and manufacturing organization (CDMO) has demonstrated momentum through its contract manufacturing business expansion and an improved product composition. The company has announced plans to invest ₹3,000 crore to expand its manufacturing capacities, with particular emphasis on high-value CDMO services. These specialized services are projected to double their revenue contribution by 2030, indicating a strategic shift toward higher-margin segments.

Brokerages have responded positively to these developments, raising their earnings forecasts for the company and maintaining 'BUY' ratings. The analyst community appears confident in the company's growth trajectory across its diversified business segments. For market participants, Laurus Labs represents exposure to the thriving contract manufacturing sector in India, which has benefited from global pharmaceutical companies seeking reliable manufacturing alternatives and cost advantages. The company's planned capacity expansion and focus on high-value CDMO services align with broader industry trends toward outsourced pharmaceutical manufacturing. Improved margins and revenue diversification typically support valuation expansion for CDMO players, making margin trajectory a key metric for investors to monitor. The pharmaceutical services sector continues to attract institutional attention as companies consolidate manufacturing operations globally.

Source: Markets-Economic Times